{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:47Z","timestamp":1791357287776,"version":"4.3.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.anai.2016.11.019","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T03:01:54Z","timestamp":1485831714000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1016","volume":"118","author":[{"given":"Ariana","family":"Eginli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-6197","authenticated-orcid":false,"given":"Guha","family":"Krishnaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.11.019_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40264-012-0008-4","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: improving the support to victims","volume":"36","author":"Roujeau","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.anai.2016.11.019_bib2","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.11.019_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1346-8138.12674","article-title":"Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Abe","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2013a comprehensive review and guide to therapy, I: systemic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.anai.2016.11.019_bib5","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis, part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.clindermatol.2015.05.005","article-title":"Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS","volume":"33","author":"Darlenski","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"F1000 Faculty Rev","key":"10.1016\/j.anai.2016.11.019_bib8","first-page":"95","article-title":"Toxic epidermal necrolysis","volume":"5","author":"Hoetzenecker","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.anai.2016.11.019_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3928\/00904481-20100922-11","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"39","author":"Treat","year":"2010","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.anai.2016.11.019_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.11.019_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/ICU.0000000000000312","article-title":"Ocular manifestations of Stevens-Johnson syndrome and their management","volume":"27","author":"Saeed","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.anai.2016.11.019_bib12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis - a comprehensive review and guide to therapy, II: ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.anai.2016.11.019_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib14","first-page":"24","article-title":"Cyclosporine for SJS\/TEN: a case series and review of the literature","volume":"87","author":"Reese","year":"2011","journal-title":"Cutis"},{"key":"10.1016\/j.anai.2016.11.019_bib15","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.anai.2016.11.019_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A\u00a0retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.anai.2016.11.019_bib18","first-page":"2446","article-title":"Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS","volume":"18","author":"Nomura","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.anai.2016.11.019_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.anai.2016.11.019_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616313539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616313539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:16:28Z","timestamp":1761052588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616313539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1081120616313539"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.11.019","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens-Johnson syndrome and toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American College of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}